Diabetic Foot Infection (DFI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Diabetic Foot Infection (DFI) Market Outlook

Thelansis’s “Diabetic Foot Infection (DFI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Foot Infection treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Diabetic Foot Infection (DFI) Overview

Diabetic foot infection (DFI) is the most prevalent complication of diabetes mellitus that results in hospitalization and is the leading cause of nontraumatic lower extremity amputation. DFI is an infection in the soft tissues or bones below the malleoli. Diagnosis relies on clinical indicators of inflammation or the presence of pus, with infections categorized as mild, moderate, or severe. Most DFI cases involve multiple microorganisms, with aerobic gram-positive cocci, primarily Staphylococcus species, being the most common pathogens. Osteomyelitis, a severe complication, often necessitates surgical intervention. Clinically detecting foot infection depends on identifying purulent discharge from an ulcer or classic signs of inflammation, such as erythema, pain, tenderness, warmth, or induration. Other suggestive signs include foul odor, necrosis, and delayed wound healing despite optimal care. Managing DFI effectively entails the appropriate antibiotic treatment, surgical drainage, dead tissue debridement and resection, proper wound care, and addressing metabolic issues. FDA-approved therapies for DFI include:

1. Zyvox: Approved for treating DFI caused by Gram-positive bacteria.
2. Zosyn: A bactericidal antibiotic approved for DFI treatment.
3. Integra Omnigraft Dermal Regeneration Matrix: Approved for specific diabetic foot ulcers.

The prognosis for DFI hinges on factors such as vascular blood supply and neuropathy. Renal failure and significant peripheral vascular disease are common risk factors for amputation, and MRSA has emerged as another risk factor for infection progression.

• Diabetic foot ulcers (DFU) are a prevalent and serious complication in the United States, affecting approximately 2 million individuals annually. The annual incidence of foot ulcers in the diabetic population ranges from 1.9% to 4.0%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: